- Home
- FULC vs LXRX Comparison
FULC vs LXRX Comparison
Compare FULC & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FULC
- LXRX
- Stock Information
- Founded
- FULC 2015
- LXRX 1995
- Country
- FULC United States
- LXRX United States
- Employees
- FULC N/A
- LXRX N/A
- Industry
- FULC Biotechnology: Pharmaceutical Preparations
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- FULC Health Care
- LXRX Health Care
- Exchange
- FULC Nasdaq
- LXRX Nasdaq
- Market Cap
- FULC 468.1M
- LXRX 541.5M
- IPO Year
- FULC 2019
- LXRX 2000
- Fundamental
- Price
- FULC $11.74
- LXRX $1.46
- Analyst Decision
- FULC Buy
- LXRX Buy
- Analyst Count
- FULC 7
- LXRX 5
- Target Price
- FULC $10.43
- LXRX $3.23
- AVG Volume (30 Days)
- FULC 922.1K
- LXRX 2.2M
- Earning Date
- FULC 10-29-2025
- LXRX 11-06-2025
- Dividend Yield
- FULC N/A
- LXRX N/A
- EPS Growth
- FULC N/A
- LXRX N/A
- EPS
- FULC N/A
- LXRX N/A
- Revenue
- FULC N/A
- LXRX $70,864,000.00
- Revenue This Year
- FULC N/A
- LXRX $66.55
- Revenue Next Year
- FULC N/A
- LXRX N/A
- P/E Ratio
- FULC N/A
- LXRX N/A
- Revenue Growth
- FULC 2752.05
- LXRX 1255.21
- 52 Week Low
- FULC $2.32
- LXRX $0.28
- 52 Week High
- FULC $12.14
- LXRX $1.66
- Technical
- Relative Strength Index (RSI)
- FULC 72.74
- LXRX 52.71
- Support Level
- FULC $7.51
- LXRX $1.36
- Resistance Level
- FULC $9.05
- LXRX $1.64
- Average True Range (ATR)
- FULC 0.80
- LXRX 0.12
- MACD
- FULC 0.27
- LXRX 0.00
- Stochastic Oscillator
- FULC 89.63
- LXRX 59.78
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.